Why using Avastin for eye disease is so difficult

BMJ (Online)

Volumn 344, Issue 7855, 2012, Pages

  Torjesen, Ingrid ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

DIABETIC MACULAR EDEMA; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; LEGAL ASPECT; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; REVIEW; WET AGE RELATED MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG COSTS; DRUG INDUSTRY; GREAT BRITAIN; HUMANS; MACULAR DEGENERATION; MARKETING; OFF-LABEL USE;

EID: 84860624026     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e3012     Document Type: Review

References (12)

1. Royal College of Ophthalmologists. RCOphth review concludes that Avastin and Lucentis are equally effective in treating wet AMD. 2011. www.rcophth.ac.uk/news.asp?itemid=647&itemTitle= RCOphth+ Review+concludes+that+ Avastin+and+Lucentis+are+equally+ effective+in+treating+wet+AMD& section=24§ionTitle=News.
2. Novartis. New analysis representing largest available dataset highlights relative safety of Lucentis® (ranibizumab) compared to unlicensed intravitreal Avastin® (bevacizumab). Press release, 4 May 2011. www.novartis.com/newsroom/media-releases/en/2011/1512519.shtml.
3. North Yorkshire and York PCT. Ranibizumab (Lucentis) and bevacizumab (Avastin) within ophthalmology. Report for board meeting, 24 January 2012. www.nyypct.nhs.uk/AboutUs/PublicBoardMeetings/2012Jan24/ Item%209%20Ranibizumab%20and%20Bevacizumab.pdf.
4. North Yorkshire and York PCT. Minutes of board meeting 24 January 2012. www.nyypct.nhs.uk/AboutUs/PublicBoardMeetings/2012Feb28/ Item%203%20BoardMins0112.pdf.
5. Scarborough and North East Yorkshire NHS Trust. First mobile community eye care centre for East Yorkshire. Press release, 14 March 2011. www.scarborough.nhs.uk/news-item.php?newsid=424.
6. Moorfields Pharmaceuticals recalls selected batches of bevacizumab intravitreal injection 1.25mg/0.05ml following reports of suspected sterile endophthalmitis. 2012. www.linkoph.com/2012/03/16/moorfields-pharmaceuticals- recalls-selected-batches-of-bevacizumabintravitreal-injection-1-25mg0-05ml- following-reports-of-suspected-sterile-endophthalmitis/.
7. European Alliance for Access to Safe Medicines. Members and funders. www.eaasm.eu/About-the-EAASM/Members-and-funders.
8. Raferty J. Avastin, Lucentis, and NICE. 28 June 2011. http://blogs.bmj.com/bmj/2011/06/28/james-raftery-avastin-lucentis-and-nice/.
9. Novartis cuts Lucentis price amid growing pressure. 2011. InPharm 2011 Oct 7. www.inpharm.com/news/168782/novartis-lucentis-price-cut-switzerland.
10. UK Medicines Information. Aflibercept (Elyea) www.ukmi.nhs.uk/ applications/ndo/record-view-open.asp?newDrugID=4653.
11. NICE. Report on the feasibility of appraising the use of bevacizumab (Avastin) to treat eye conditions. Press release, 6 December 2010. www.nice.org.uk/newsroom/pressreleases/BevacizumabAvastinToTreatEyeConditions. jsp.
12. Macular Disease Society. Government must act on Avastin. www.maculardisease.org/news.asp?itemid=300&itemTitle= Government+must+act+on+Avastin§ion=28§ionTitle=News.